NEW YORK, April 02, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ...

Intra-Cellular’s 2022 commercial for its bipolar depression therapy Caplyta “Let in the Lyte” has been crowned this year’s Fierce Madness Drug Ad Tournament winner, beating out GSK and its shingles ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. In a statistically ...

NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) ...

The sNDA submission is based on positive results from Studies 501 and 502 demonstrating CAPLYTA’s robust antidepressant efficacy and favorable safety and tolerability profile CAPLYTA, if approved as ...

Intra-Cellular's share price has increased by 450% over a five-year period and over 50% in the past year. The company's success is attributed to its approved drug, Caplyta, which has driven ...

“We are encouraged by CAPLYTA’s strong growth trajectory in the third quarter and look forward to further growth in the remainder of 2024 and beyond. We are on track to submit our sNDA for the ...

Caplyta (lumateperone) has scored a label extension into the depression setting, underscoring the belief Johnson & Johnson (J&J) saw in the drug when it acquired original developer Intra-Cellular ...

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders, has been garnering significant attention from ...

CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase CAPLYTA’s strong prescription uptake continues: Q3 2024 ...